6CM
PRAX icon

683 Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

683 Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11,481
Closed -$256K – 230
2023
Q4 		$256K Buy
+11,481
New +$207K 0.02% 148

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

683 Capital Management's PRAX Position: Q1 2024 in Review

683 Capital Management sold out of Praxis Precision Medicines (PRAX) in Q1 2024, closing a stake of 11,481 shares — an estimated $256K sold.

683 Capital Management first reported a position in PRAX in Q4 2023 and held it in 1 quarter. The position peaked at $256K in Q4 2023. 111 funds tracked by Wall St. Rank hold PRAX as of Q1 2024.

  • 683 Capital Management reported no remaining Praxis Precision Medicines position as of Q1 2024 after selling out during the quarter.
  • 683 Capital Management sold 11,481 Praxis Precision Medicines shares in Q1 2024, an estimated $256K.
  • 683 Capital Management first reported a position in Praxis Precision Medicines in Q4 2023 and held it in 1 quarter.
  • 683 Capital Management's Praxis Precision Medicines position peaked at $256K in Q4 2023.
  • 111 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2024.

Based on 683 Capital Management's 13F filing for Q1 2024, filed 15 May 2024.